Quick Takeaways
- MDGL - MADRIGAL PHARMACEUTICALS, INC. financial facts are built from SEC company filings data.
- Latest metrics period on this page: Q4 2025.
- Headline metric: Return On Equity -42%.
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q4 2025.
Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.
See Original FilingLatest SEC snapshot (2026-02-12) highlights Return On Equity -42.5%, Return On Assets -16.3%, and Operating Margin -18.6%.
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
47.1/100
Caution Confidence high
-42%
Metric score 0.0/100
-16%
Metric score 0.0/100
Debt-to-equity, Revenues YoY, and NetIncomeLoss YoY
Return On Equity, Return On Assets, and Operating Margin
Return On Equity
-42%
YoY: -47%
Industry median: -43% (n=671)
Return On Assets
-16%
YoY: -55%
Industry median: -48% (n=669)
Operating Margin
-19%
YoY: -89%
Industry median: -128% (n=298)
Current Ratio
4.02x
YoY: -34%
Industry median: 3.39x (n=667)
Quick Ratio
3.6x
YoY: -82%
Industry median: 2.02x (n=287)
Debt-to-equity
0.58x
YoY: +132%
Industry median: 0.28x (n=634)
Revenues YoY
432%
YoY:
Industry median: 5% (n=103)
NetIncomeLoss YoY
38%
YoY:
Industry median: -0.54% (n=641)
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -42% | -47% |
| Return On Assets | -16% | -55% |
| Operating Margin | -19% | -89% |
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 4.02x | -34% |
| Quick Ratio | 3.6x | -82% |
| Debt-to-equity | 0.58x | +132% |
| Metric | Latest value | YoY change |
|---|---|---|
| Revenues YoY | 432% | |
| NetIncomeLoss YoY | 38% |
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 22,939,969 | |
| Common Stock, Shares, Outstanding | 22,842,073 | +3.8% |
| Common Stock, Value, Issued | $2,000 | 0% |
| Weighted Average Number of Shares Outstanding, Basic | 22,434,310 | +5.5% |
| Weighted Average Number of Shares Outstanding, Diluted | 22,434,310 | +5.5% |
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.